Efficacy and safety of neoadjuvant disitamab vedotin (DV) in combination with toripalimab (Tor) and concurrent/sequential chemotherapy (chemo) in patients with HR-negative, HER2-low breast cancer: A randomized multicenter phase 2 study.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Fudan University Shanghai Cancer Center, Zhejiang Cancer Hospital, Hunan Cancer Hospital, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an Jiaotong University, Central South University, Xiangya Hospital Central South University, Nanjing Drum Tower Hospital, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, First Affiliated Hospital of Kunming Medical University, Sichuan Cancer Hospital, Nanjing University of Science and Technology, The Affiliated Yongchuan Hospital of Chongqing Medical University, First Affiliated Hospital of Bengbu Medical College, Tongji University
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W7162511302
Cites:
Cited by:
Related to: